ArticleAAPS PharmSciTech2026
Personalized 3D-Printed Finger Splints Derived from CT Data Incorporating Multi-Drug Bilayer Nanofiber Delivery Systems.
Article in AAPS PharmSciTech, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Finger fractures are among the most common musculoskeletal injuries, yet conventional splints for finger are often poorly fitted, uncomfortable, and incapable of providing localized therapeutic support, which can delay healing and increase complications. This study presents a computed tomography (CT)-guided, patient-specific 3D-printed finger splint incorporating a bilayer electrospun nanofiber coating mat for localized dual delivery of hydrocortisone (HCT) and ibuprofen (IBU), providing concurrent anti-inflammatory and analgesic therapy through two distinct mechanisms. CT data were segmented to generate customized splint geometries, which were fabricated using fused deposition modeling (FDM) to produce a rigid polylactic acid outer shell and stereolithography (SLA) to create a flexible inner layer. The inner surface was sequentially coated with IBU-loaded polycaprolactone nanofibers then HCT-loaded pullulan. Comprehensive characterization by SEM, FTIR, DSC, and XRD confirmed smooth, bead-free PCL nanofibers, strong adhesion to the microtextured SLA surface, and amorphous dispersion of both drugs with entrapment efficiencies above 90%. In vitro release studies demonstrated rapid HCT liberation of 79.68 ± 0.17% within 2 h, and IBU release of 51.75 ± 4.35% within 24 h. Ex vivo porcine skin permeation studies showed significantly enhanced drug delivery compared with pure drug controls, with cumulative permeation values of 155.52 ± 19.97 µg/cm
Indexed as
Identifiers
41845109What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.